When reviewed retrospectively and sequentially, there was a clear trend towards using higher doses per level over time, despite the successful fusion rates seen at the lower doses per level, following a "more is better" philosophy.
← all excerpts
A Narrative Review on Recombinant Human Bone Morphogenetic Protein 2: Where Are We Now?
1
—
—